Article Type
Changed
Wed, 09/13/2017 - 12:14
Display Headline
Is cardiac stress testing appropriate in asymptomatic adults at low risk?

A 48-year-old insurance executive is offered the option of several health insurance packages at the time of a promotion. He is healthy and a non-smoker; both his parents are alive and well; and he takes only vitamins and fish oil supplements on a regular basis. His levels of total cholesterol, low-density lipoprotein cholesterol, and high-density lipoprotein cholesterol are all in the normal range, as is his blood pressure. He plans to purchase the lowest price policy, but wants to know if he should also get a stress test to best guide his care.

GUIDELINES RECOMMEND AGAINST TESTING

Patients who are at low risk of disease and without symptoms should not undergo cardiac stress testing. The test is unlikely to be helpful in these patients and may expose them to harm unnecessarily. Cardiac stress testing such as exercise electrocardiography is most useful in patients who have chest pain and shortness of breath on exertion, to look for underlying cardiovascular disease. Despite this, the test is often used inappropriately as part of a routine health evaluation in low-risk, asymptomatic people, such as this patient.

Recent high-quality guidelines address exercise electrocardiography as a screening test for cardiovascular disease in asymptomatic, low-risk adults.

The US Preventive Services Task Force 2012 guideline1 recommends against screening with exercise electrocardiography for predicting coronary heart disease events in adults with no symptoms and at low risk of these events. A systematic review found no data from randomized controlled trials or prospective cohort studies of this test to screen asymptomatic adults compared with no screening.2

The American Academy of Family Physicians (AAFP) 2012 guideline3 recommends against routine screening with exercise electrocardiography either for the presence of severe coronary artery stenosis or for predicting coronary events in adults at low risk. The AAFP guideline notes that there is moderate or high certainty of no net benefit or that the harms outweigh the benefits of exercise electrocardiography in adults at low risk and without symptoms.

The 2010 joint guideline of the American College of Cardiology and the American Heart Association4 does not comment on the role of screening exercise electrocardiography in low-risk asymptomatic adults, but states that a physician may consider ordering exercise electrocardiography in asymptomatic adults at intermediate risk of coronary heart disease. The guideline recommends that the individual physician decide whether screening exercise electrocardiography is warranted in a patient at intermediate risk.

The Choosing Wisely initiative

As part of the Choosing Wisely initiative of the American Board of Internal Medicine Foundation, a number of medical specialty societies have published lists of recommendations and issues that physicians and patients should question and discuss. Cardiac stress testing in low-risk asymptomatic patients is on the list of a number of organizations, including the American College of Physicians, the American College of Cardiology, the AAFP, and the American Society of Nuclear Cardiology. These lists can be found at www.choosingwisely.org.

 

 

POSSIBLE HARM ASSOCIATED WITH CARDIAC STRESS TESTING

The overall risk of sudden cardiac death or an event that requires hospitalization during exercise electrocardiography is very small, estimated to be 1 per 10,000 tests, and the risk is probably even less in patients at low risk.5 But the risk of potential downstream harm from additional testing or interventions may be greater than direct harm. Still, no study has yet assessed harm associated with follow-up testing or interventions after screening with exercise electrocardiography.

On the basis of large, population-based registries that include symptomatic persons, the risk of any serious adverse event as a result of angiography is about 1.7%; this includes a 0.1% risk of death, a 0.05% risk of myocardial infarction, a 0.07% risk of stroke, and a 0.4% risk of arrhythmia.6 In addition, coronary angiography is associated with an average effective radiation dose of 7 mSv and myocardial perfusion imaging with a dose of 15.6 mSv.7 These are approximately two times and five times the amount of radiation an average person in the United States receives per year from exposure to ambient radiation (3 mSv).

Several studies that included symptomatic and asymptomatic patients who had undergone angiography reported that between 39% and 85% of patients had no coronary artery disease. This means that many patients were subjected to the risks of invasive testing and treatment without the possibility of benefit. Patients who receive lipid-lowering therapy or aspirin because of an abnormal exercise electrocardiogram are also exposed to the risks related to those interventions.

THE CLINICAL BOTTOM LINE

On the basis of current data, the insurance executive should not get a stress test because the results of the test are unlikely to have an impact on his medical management, are unlikely to improve his clinical outcome, and carry a small risk of harm. Low-risk, asymptomatic people with a positive stress test have the same mortality rate as those who have a negative stress test, and its usefulness beyond traditional risk-factor assessment in motivating patients and guiding therapy has not been established.8 In addition, the rate of false-positive results with exercise stress testing is as high as 71%.9 Although the risk of an adverse event from the initial stress test is low, ie, 1 serious event in 10,000 tests, the risk of subsequent cardiac catheterization after a positive test is significantly higher, ie, 170 serious events in 10,000 tests. For these reasons, the potential harm of exercise electrocardiography outweighs the benefits in this patient.

References
  1. Moyer VAUS Preventive Services Task Force. Screening for coronary heart disease with electrocardiography: US Preventive Services Task Force recommendation statement. Ann Intern Med 2012; 157:512518.
  2. Chou R, Arora B, Dana T, Fu R, Walker M, Humphrey L. Screening asymptomatic adults with resting or exercise electrocardiography: a review of the evidence for the US Preventive Services Task Force. Ann Intern Med 2011; 155:375385.
  3. Leawood KS; American Academy of Family Physicians (AAFP). Summary of recommendations for clinical preventive services. American Academy of Family Physicians (AAFP); 2012. http://www.guideline.gov/content.aspx?id=47554. Accessed May 12, 2014.
  4. Greenland P, Alpert JS, Beller GA, et al; American College of Cardiology Foundation; American Heart Association. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2010; 56:e50e103.
  5. Myers J, Arena R, Franklin B, et al; American Heart Association Committee on Exercise, Cardiac Rehabilitation, and Prevention of the Council on Clinical Cardiology, the Council on Nutrition, Physical Activity, and Metabolism, and the Council on Cardiovascular Nursing. Recommendations for clinical exercise laboratories: a scientific statement from the American Heart Association. Circulation 2009; 119:31443161.
  6. Noto TJ, Johnson LW, Krone R, et al. Cardiac catheterization 1990: a report of the Registry of the Society for Cardiac Angiography and Interventions (SCA&I). Cathet Cardiovasc Diagn 1991; 24:7583.
  7. Fazel R, Krumholz HM, Wang Y, et al. Exposure to low-dose ionizing radiation from medical imaging procedures. N Engl J Med 2009; 361:849857.
  8. Pilote L, Pashkow F, Thomas JD, et al. Clinical yield and cost of exercise treadmill testing to screen for coronary artery disease in asymptomatic adults. Am J Cardiol 1998; 81:219224.
  9. Hopkirk JA, Uhl GS, Hickman JR, Fischer J, Medina A. Discriminant value of clinical and exercise variables in detecting significant coronary artery disease in asymptomatic men. J Am Coll Cardiol 1984; 3:887894.
Article PDF
Author and Disclosure Information

Cynthia D. Smith, MD, FACP
Senior Physician Educator, Medical Education, American College of Physicians, and Adjunct Associate Professor, Perelman School of Medicine, Philadelphia, PA

Patrick C. Alguire, MD, FACP
Senior Vice President, Medical Education, American College of Physicians, Philadelphia, PA

Address: Cynthia D. Smith, MD, Medical Education Division, American College of Physicians, 190 North Independence Mall West, Philadelphia, PA 19106; e-mail: [email protected]

Dr. Smith has disclosed stock holdings and spousal employment at Merck and Company. Dr. Alguire has disclosed royalty payments from UpToDate and ownership interest in Amgen, Bristol-Myers Squibb, Covidien, Dupont, Express Scripts, GlaxoSmithKline, Medtronics, Stryker, Teva Pharmaceutical Industries, and Zimmer Orthopedics.

Smart Testing is a joint project between Cleveland Clinic Journal of Medicine and the American College of Physicians (ACP). The series, an extension of the ACP High Value Care initiative (hvc.acponline.org/index.html), provides recommendations for improving patient outcomes while reducing unnecessary tests and treatments.

Issue
Cleveland Clinic Journal of Medicine - 81(7)
Publications
Topics
Page Number
405-406
Sections
Author and Disclosure Information

Cynthia D. Smith, MD, FACP
Senior Physician Educator, Medical Education, American College of Physicians, and Adjunct Associate Professor, Perelman School of Medicine, Philadelphia, PA

Patrick C. Alguire, MD, FACP
Senior Vice President, Medical Education, American College of Physicians, Philadelphia, PA

Address: Cynthia D. Smith, MD, Medical Education Division, American College of Physicians, 190 North Independence Mall West, Philadelphia, PA 19106; e-mail: [email protected]

Dr. Smith has disclosed stock holdings and spousal employment at Merck and Company. Dr. Alguire has disclosed royalty payments from UpToDate and ownership interest in Amgen, Bristol-Myers Squibb, Covidien, Dupont, Express Scripts, GlaxoSmithKline, Medtronics, Stryker, Teva Pharmaceutical Industries, and Zimmer Orthopedics.

Smart Testing is a joint project between Cleveland Clinic Journal of Medicine and the American College of Physicians (ACP). The series, an extension of the ACP High Value Care initiative (hvc.acponline.org/index.html), provides recommendations for improving patient outcomes while reducing unnecessary tests and treatments.

Author and Disclosure Information

Cynthia D. Smith, MD, FACP
Senior Physician Educator, Medical Education, American College of Physicians, and Adjunct Associate Professor, Perelman School of Medicine, Philadelphia, PA

Patrick C. Alguire, MD, FACP
Senior Vice President, Medical Education, American College of Physicians, Philadelphia, PA

Address: Cynthia D. Smith, MD, Medical Education Division, American College of Physicians, 190 North Independence Mall West, Philadelphia, PA 19106; e-mail: [email protected]

Dr. Smith has disclosed stock holdings and spousal employment at Merck and Company. Dr. Alguire has disclosed royalty payments from UpToDate and ownership interest in Amgen, Bristol-Myers Squibb, Covidien, Dupont, Express Scripts, GlaxoSmithKline, Medtronics, Stryker, Teva Pharmaceutical Industries, and Zimmer Orthopedics.

Smart Testing is a joint project between Cleveland Clinic Journal of Medicine and the American College of Physicians (ACP). The series, an extension of the ACP High Value Care initiative (hvc.acponline.org/index.html), provides recommendations for improving patient outcomes while reducing unnecessary tests and treatments.

Article PDF
Article PDF

A 48-year-old insurance executive is offered the option of several health insurance packages at the time of a promotion. He is healthy and a non-smoker; both his parents are alive and well; and he takes only vitamins and fish oil supplements on a regular basis. His levels of total cholesterol, low-density lipoprotein cholesterol, and high-density lipoprotein cholesterol are all in the normal range, as is his blood pressure. He plans to purchase the lowest price policy, but wants to know if he should also get a stress test to best guide his care.

GUIDELINES RECOMMEND AGAINST TESTING

Patients who are at low risk of disease and without symptoms should not undergo cardiac stress testing. The test is unlikely to be helpful in these patients and may expose them to harm unnecessarily. Cardiac stress testing such as exercise electrocardiography is most useful in patients who have chest pain and shortness of breath on exertion, to look for underlying cardiovascular disease. Despite this, the test is often used inappropriately as part of a routine health evaluation in low-risk, asymptomatic people, such as this patient.

Recent high-quality guidelines address exercise electrocardiography as a screening test for cardiovascular disease in asymptomatic, low-risk adults.

The US Preventive Services Task Force 2012 guideline1 recommends against screening with exercise electrocardiography for predicting coronary heart disease events in adults with no symptoms and at low risk of these events. A systematic review found no data from randomized controlled trials or prospective cohort studies of this test to screen asymptomatic adults compared with no screening.2

The American Academy of Family Physicians (AAFP) 2012 guideline3 recommends against routine screening with exercise electrocardiography either for the presence of severe coronary artery stenosis or for predicting coronary events in adults at low risk. The AAFP guideline notes that there is moderate or high certainty of no net benefit or that the harms outweigh the benefits of exercise electrocardiography in adults at low risk and without symptoms.

The 2010 joint guideline of the American College of Cardiology and the American Heart Association4 does not comment on the role of screening exercise electrocardiography in low-risk asymptomatic adults, but states that a physician may consider ordering exercise electrocardiography in asymptomatic adults at intermediate risk of coronary heart disease. The guideline recommends that the individual physician decide whether screening exercise electrocardiography is warranted in a patient at intermediate risk.

The Choosing Wisely initiative

As part of the Choosing Wisely initiative of the American Board of Internal Medicine Foundation, a number of medical specialty societies have published lists of recommendations and issues that physicians and patients should question and discuss. Cardiac stress testing in low-risk asymptomatic patients is on the list of a number of organizations, including the American College of Physicians, the American College of Cardiology, the AAFP, and the American Society of Nuclear Cardiology. These lists can be found at www.choosingwisely.org.

 

 

POSSIBLE HARM ASSOCIATED WITH CARDIAC STRESS TESTING

The overall risk of sudden cardiac death or an event that requires hospitalization during exercise electrocardiography is very small, estimated to be 1 per 10,000 tests, and the risk is probably even less in patients at low risk.5 But the risk of potential downstream harm from additional testing or interventions may be greater than direct harm. Still, no study has yet assessed harm associated with follow-up testing or interventions after screening with exercise electrocardiography.

On the basis of large, population-based registries that include symptomatic persons, the risk of any serious adverse event as a result of angiography is about 1.7%; this includes a 0.1% risk of death, a 0.05% risk of myocardial infarction, a 0.07% risk of stroke, and a 0.4% risk of arrhythmia.6 In addition, coronary angiography is associated with an average effective radiation dose of 7 mSv and myocardial perfusion imaging with a dose of 15.6 mSv.7 These are approximately two times and five times the amount of radiation an average person in the United States receives per year from exposure to ambient radiation (3 mSv).

Several studies that included symptomatic and asymptomatic patients who had undergone angiography reported that between 39% and 85% of patients had no coronary artery disease. This means that many patients were subjected to the risks of invasive testing and treatment without the possibility of benefit. Patients who receive lipid-lowering therapy or aspirin because of an abnormal exercise electrocardiogram are also exposed to the risks related to those interventions.

THE CLINICAL BOTTOM LINE

On the basis of current data, the insurance executive should not get a stress test because the results of the test are unlikely to have an impact on his medical management, are unlikely to improve his clinical outcome, and carry a small risk of harm. Low-risk, asymptomatic people with a positive stress test have the same mortality rate as those who have a negative stress test, and its usefulness beyond traditional risk-factor assessment in motivating patients and guiding therapy has not been established.8 In addition, the rate of false-positive results with exercise stress testing is as high as 71%.9 Although the risk of an adverse event from the initial stress test is low, ie, 1 serious event in 10,000 tests, the risk of subsequent cardiac catheterization after a positive test is significantly higher, ie, 170 serious events in 10,000 tests. For these reasons, the potential harm of exercise electrocardiography outweighs the benefits in this patient.

A 48-year-old insurance executive is offered the option of several health insurance packages at the time of a promotion. He is healthy and a non-smoker; both his parents are alive and well; and he takes only vitamins and fish oil supplements on a regular basis. His levels of total cholesterol, low-density lipoprotein cholesterol, and high-density lipoprotein cholesterol are all in the normal range, as is his blood pressure. He plans to purchase the lowest price policy, but wants to know if he should also get a stress test to best guide his care.

GUIDELINES RECOMMEND AGAINST TESTING

Patients who are at low risk of disease and without symptoms should not undergo cardiac stress testing. The test is unlikely to be helpful in these patients and may expose them to harm unnecessarily. Cardiac stress testing such as exercise electrocardiography is most useful in patients who have chest pain and shortness of breath on exertion, to look for underlying cardiovascular disease. Despite this, the test is often used inappropriately as part of a routine health evaluation in low-risk, asymptomatic people, such as this patient.

Recent high-quality guidelines address exercise electrocardiography as a screening test for cardiovascular disease in asymptomatic, low-risk adults.

The US Preventive Services Task Force 2012 guideline1 recommends against screening with exercise electrocardiography for predicting coronary heart disease events in adults with no symptoms and at low risk of these events. A systematic review found no data from randomized controlled trials or prospective cohort studies of this test to screen asymptomatic adults compared with no screening.2

The American Academy of Family Physicians (AAFP) 2012 guideline3 recommends against routine screening with exercise electrocardiography either for the presence of severe coronary artery stenosis or for predicting coronary events in adults at low risk. The AAFP guideline notes that there is moderate or high certainty of no net benefit or that the harms outweigh the benefits of exercise electrocardiography in adults at low risk and without symptoms.

The 2010 joint guideline of the American College of Cardiology and the American Heart Association4 does not comment on the role of screening exercise electrocardiography in low-risk asymptomatic adults, but states that a physician may consider ordering exercise electrocardiography in asymptomatic adults at intermediate risk of coronary heart disease. The guideline recommends that the individual physician decide whether screening exercise electrocardiography is warranted in a patient at intermediate risk.

The Choosing Wisely initiative

As part of the Choosing Wisely initiative of the American Board of Internal Medicine Foundation, a number of medical specialty societies have published lists of recommendations and issues that physicians and patients should question and discuss. Cardiac stress testing in low-risk asymptomatic patients is on the list of a number of organizations, including the American College of Physicians, the American College of Cardiology, the AAFP, and the American Society of Nuclear Cardiology. These lists can be found at www.choosingwisely.org.

 

 

POSSIBLE HARM ASSOCIATED WITH CARDIAC STRESS TESTING

The overall risk of sudden cardiac death or an event that requires hospitalization during exercise electrocardiography is very small, estimated to be 1 per 10,000 tests, and the risk is probably even less in patients at low risk.5 But the risk of potential downstream harm from additional testing or interventions may be greater than direct harm. Still, no study has yet assessed harm associated with follow-up testing or interventions after screening with exercise electrocardiography.

On the basis of large, population-based registries that include symptomatic persons, the risk of any serious adverse event as a result of angiography is about 1.7%; this includes a 0.1% risk of death, a 0.05% risk of myocardial infarction, a 0.07% risk of stroke, and a 0.4% risk of arrhythmia.6 In addition, coronary angiography is associated with an average effective radiation dose of 7 mSv and myocardial perfusion imaging with a dose of 15.6 mSv.7 These are approximately two times and five times the amount of radiation an average person in the United States receives per year from exposure to ambient radiation (3 mSv).

Several studies that included symptomatic and asymptomatic patients who had undergone angiography reported that between 39% and 85% of patients had no coronary artery disease. This means that many patients were subjected to the risks of invasive testing and treatment without the possibility of benefit. Patients who receive lipid-lowering therapy or aspirin because of an abnormal exercise electrocardiogram are also exposed to the risks related to those interventions.

THE CLINICAL BOTTOM LINE

On the basis of current data, the insurance executive should not get a stress test because the results of the test are unlikely to have an impact on his medical management, are unlikely to improve his clinical outcome, and carry a small risk of harm. Low-risk, asymptomatic people with a positive stress test have the same mortality rate as those who have a negative stress test, and its usefulness beyond traditional risk-factor assessment in motivating patients and guiding therapy has not been established.8 In addition, the rate of false-positive results with exercise stress testing is as high as 71%.9 Although the risk of an adverse event from the initial stress test is low, ie, 1 serious event in 10,000 tests, the risk of subsequent cardiac catheterization after a positive test is significantly higher, ie, 170 serious events in 10,000 tests. For these reasons, the potential harm of exercise electrocardiography outweighs the benefits in this patient.

References
  1. Moyer VAUS Preventive Services Task Force. Screening for coronary heart disease with electrocardiography: US Preventive Services Task Force recommendation statement. Ann Intern Med 2012; 157:512518.
  2. Chou R, Arora B, Dana T, Fu R, Walker M, Humphrey L. Screening asymptomatic adults with resting or exercise electrocardiography: a review of the evidence for the US Preventive Services Task Force. Ann Intern Med 2011; 155:375385.
  3. Leawood KS; American Academy of Family Physicians (AAFP). Summary of recommendations for clinical preventive services. American Academy of Family Physicians (AAFP); 2012. http://www.guideline.gov/content.aspx?id=47554. Accessed May 12, 2014.
  4. Greenland P, Alpert JS, Beller GA, et al; American College of Cardiology Foundation; American Heart Association. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2010; 56:e50e103.
  5. Myers J, Arena R, Franklin B, et al; American Heart Association Committee on Exercise, Cardiac Rehabilitation, and Prevention of the Council on Clinical Cardiology, the Council on Nutrition, Physical Activity, and Metabolism, and the Council on Cardiovascular Nursing. Recommendations for clinical exercise laboratories: a scientific statement from the American Heart Association. Circulation 2009; 119:31443161.
  6. Noto TJ, Johnson LW, Krone R, et al. Cardiac catheterization 1990: a report of the Registry of the Society for Cardiac Angiography and Interventions (SCA&I). Cathet Cardiovasc Diagn 1991; 24:7583.
  7. Fazel R, Krumholz HM, Wang Y, et al. Exposure to low-dose ionizing radiation from medical imaging procedures. N Engl J Med 2009; 361:849857.
  8. Pilote L, Pashkow F, Thomas JD, et al. Clinical yield and cost of exercise treadmill testing to screen for coronary artery disease in asymptomatic adults. Am J Cardiol 1998; 81:219224.
  9. Hopkirk JA, Uhl GS, Hickman JR, Fischer J, Medina A. Discriminant value of clinical and exercise variables in detecting significant coronary artery disease in asymptomatic men. J Am Coll Cardiol 1984; 3:887894.
References
  1. Moyer VAUS Preventive Services Task Force. Screening for coronary heart disease with electrocardiography: US Preventive Services Task Force recommendation statement. Ann Intern Med 2012; 157:512518.
  2. Chou R, Arora B, Dana T, Fu R, Walker M, Humphrey L. Screening asymptomatic adults with resting or exercise electrocardiography: a review of the evidence for the US Preventive Services Task Force. Ann Intern Med 2011; 155:375385.
  3. Leawood KS; American Academy of Family Physicians (AAFP). Summary of recommendations for clinical preventive services. American Academy of Family Physicians (AAFP); 2012. http://www.guideline.gov/content.aspx?id=47554. Accessed May 12, 2014.
  4. Greenland P, Alpert JS, Beller GA, et al; American College of Cardiology Foundation; American Heart Association. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2010; 56:e50e103.
  5. Myers J, Arena R, Franklin B, et al; American Heart Association Committee on Exercise, Cardiac Rehabilitation, and Prevention of the Council on Clinical Cardiology, the Council on Nutrition, Physical Activity, and Metabolism, and the Council on Cardiovascular Nursing. Recommendations for clinical exercise laboratories: a scientific statement from the American Heart Association. Circulation 2009; 119:31443161.
  6. Noto TJ, Johnson LW, Krone R, et al. Cardiac catheterization 1990: a report of the Registry of the Society for Cardiac Angiography and Interventions (SCA&I). Cathet Cardiovasc Diagn 1991; 24:7583.
  7. Fazel R, Krumholz HM, Wang Y, et al. Exposure to low-dose ionizing radiation from medical imaging procedures. N Engl J Med 2009; 361:849857.
  8. Pilote L, Pashkow F, Thomas JD, et al. Clinical yield and cost of exercise treadmill testing to screen for coronary artery disease in asymptomatic adults. Am J Cardiol 1998; 81:219224.
  9. Hopkirk JA, Uhl GS, Hickman JR, Fischer J, Medina A. Discriminant value of clinical and exercise variables in detecting significant coronary artery disease in asymptomatic men. J Am Coll Cardiol 1984; 3:887894.
Issue
Cleveland Clinic Journal of Medicine - 81(7)
Issue
Cleveland Clinic Journal of Medicine - 81(7)
Page Number
405-406
Page Number
405-406
Publications
Publications
Topics
Article Type
Display Headline
Is cardiac stress testing appropriate in asymptomatic adults at low risk?
Display Headline
Is cardiac stress testing appropriate in asymptomatic adults at low risk?
Sections
Disallow All Ads
Alternative CME
Article PDF Media